Efavirenz DuPont Pharmaceuticals Co

Area of Science:

• Virology
• Pharmacology
• Infectious Diseases

Background:

• Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for treating viral infections, including HIV.
• DuPont Merck submitted an NDA to the US FDA for efavirenz (Sustiva) in June 1998.
• Efavirenz is being evaluated in various combinations for HIV treatment, including with protease inhibitors and other antiretrovirals.

Purpose of the Study:

• To evaluate the efficacy of efavirenz in treating HIV infection, both as monotherapy and in combination regimens.
• To assess the impact of efavirenz-based therapies on viral load and CD4 cell counts in HIV-infected patients.
• To explore the potential of efavirenz in combination with novel agents like T-20 for treatment-experienced patients.

Main Methods:

• Clinical trials involving HIV-infected patients receiving efavirenz as monotherapy or in dual and triple combination therapies.
• Studies included assessments of HIV-RNA levels in plasma and cerebrospinal fluid, and CD4 cell counts.
• Phase III studies and pilot trials were conducted to evaluate safety, pharmacokinetics, and antiviral activity.

Main Results:

• Efavirenz combination therapies achieved HIV-RNA levels below the level of detection (fewer than 400 copies/ml) in plasma and CSF.
• A phase III study showed significant reduction in viral levels and increased CD4 cell levels when efavirenz was combined with zidovudine and lamivudine.
• In clinical trials, 82% of patients achieved undetectable viral load with efavirenz and indinavir combination therapy.

Conclusions:

• Efavirenz demonstrates significant efficacy in suppressing HIV viral load and improving CD4 cell counts.
• Combination therapy including efavirenz is a promising strategy for managing HIV infection.
• Further research is ongoing to evaluate efavirenz in novel combinations for various patient populations.